Compound dietary fiber chewable tablet as well as preparation method and application thereof

By using natural raw materials such as konjac, ginger, bamboo shoots, wheat bran, etc., combined with vitamin B6 and organic selenium, the problem of intestinal flora imbalance caused by insufficient dietary fiber intake is solved, and the intestines are realized The remodeling of the tract flora and the regulation of the immune system have the effects of lowering blood sugar and blood lipids, and is suitable for preventing diseases such as diabetes and rheumatoid arthritis.

CN118975673APending Publication Date: 2024-11-19SHANXI BETHUNE HOSPITAL (SHANXI ACAD OF MEDICAL SCI SHANXI HOSPITAL OF TONGJI HOSPITAL AFFILIATED TO TONGJI MEDICAL COLLEGE OF HUAZHONG UNIV OF SCI & TECH SHANXI MEDICAL UNIV THIRD HOSPITAL SHANXI MEDICAL UNIV THIRD CLINICAL COLLEGE OF MEDICINE)
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410913365.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-09
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

The dietary fiber intake of modern people is reduced, resulting in intestinal flora imbalance, affecting health, and increasing the risk of autoimmune diseases such as diabetes and rheumatoid arthritis. The existing chewable tablets lack effective functional and natural ingredients.

Method used

Develop a compound dietary fiber chewable tablet, using natural raw materials such as konjac, ginger, bamboo shoots, wheat bran, etc., combined with vitamin B6 and organic selenium, extract dietary fiber through Aspergillus fermentation method, and combined with adhesives such as carrageenan to prepare It becomes a sweet and sour functional chewable tablet, reshapes the intestinal flora, regulates the immune status, and lowers blood sugar and blood lipids.

Benefits of technology

The chewable tablets significantly improve the metabolism of lactic acid and butyric acid in the intestinal flora, regulate the immune system, prevent and relieve diseases such as type 1 diabetes and rheumatoid arthritis, and have the effect of lowering blood sugar and blood lipids. They have a good taste and are easy to use. Absorption, broad market prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118975673A_ABST
    Figure CN118975673A_ABST
Patent Text Reader

Abstract

The invention discloses a compound dietary fiber chewable tablet as well as a preparation method and application thereof, and the compound dietary fiber chewable tablet comprises the following raw materials in parts by weight: 900 parts of dietary fiber, 1-3 parts of vitamin B6, 0.01-0.03 part of organic selenium, 70-80 parts of an adhesive, 5-10 parts of citric acid, 3-5 parts of xylitol and 5-15 parts of magnesium stearate. The dietary fibers are formed by mixing konjak dietary fibers, jerusalem artichoke dietary fibers, bamboo shoot dietary fibers and wheat bran dietary fibers. The compound dietary fiber chewable tablet is good in form, sour, sweet and delicious, convenient to carry and eat, and capable of well supplementing vitamin B6, selenium and dietary fibers; the traditional Chinese medicine composition has the advantages that the traditional Chinese medicine composition can be used for preparing the traditional Chinese medicine composition, the intestinal flora can be remodeled, the abundance of Lactobacillus and Akkermansiaceae bacteria can be obviously improved, the lactic acid and butyric acid metabolism of the intestinal flora can be enhanced, the immune state of the body can be regulated, and the symptoms of autoimmune diseases such as type 1 diabetes mellitus and rheumatoid arthritis can be prevented and relieved; meanwhile, the chewable tablet has the functions of reducing blood sugar and blood fat, and is a pure natural, safe and sugar-free functional chewable tablet.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of functional foods and relates to a compound dietary fiber chewable tablet and a preparation method and application thereof. Background Art

[0002] There are a large number of microorganisms living in the human body, especially intestinal microorganisms, which are the most important "endogenous environmental factors" of the human body. There are more than 100 bacterial genera and more than 400 bacterial species, which is about 10 times the number of human cells. Modern research shows that human health is closely related to intestinal microorganisms. Intestinal flora imbalance caused by various reasons will affect human health and lead to various diseases: such as inflammatory bowel disease (IBDs), celiac disease, irritable bowel syndrome (IBS), colorectal cancer (CRC), chronic liver disease or pancreatic lesions.

[0003] Dietary fiber is the "seventh nutrient" after water, protein, fat, minerals, vitamins, and carbohydrates. The Chinese Nutrition Society recommends a normal adult dietary fiber intake of 25-30g / d. Interestingly, the human body lacks the enzymes required to digest dietary fiber, and various dietary fibers are not digested and absorbed in the small intestine. However, in the colon, they can be used as an energy source by specific resident bacteria. Different intestinal microorganisms metabolize these indigestible dietary fibers into various metabolites, such as short-chain fatty acids (SCFAs), pathogen-associated pattern molecules (PAMPs), peptidoglycans, and lipopolysaccharides (LPS). These metabolites interact with receptors on host cells, thereby activating or inhibiting cell signaling pathways and playing many physiological roles, such as regulating energy homeostasis, sugar / lipid metabolism, inflammation, and even immunity and cancer.

[0004] However, with the continuous improvement of living standards, the diet has become more and more refined, "coarse grains" have gradually left our tables, "big fish and big meat" have become commonplace, and the intake of dietary fiber has also decreased significantly. In order to reduce the incidence of diabetes, obesity, etc., it is necessary to maintain a diet structure with a combination of coarse and fine grains and balanced nutrition. Therefore, the current research on dietary fiber has extremely far-reaching practical significance for improving the health level of the Chinese people.

[0005] Chewable tablets are usually made by the pharmaceutical industry into tablets that are easy for patients to carry and take. The tablets are chewed to increase the surface area, which can be better dissolved and absorbed in the body. With the continuous improvement of living standards, the public's acceptance of chewable tablets has been further improved, not only staying at drug preparations, but also gradually, chewable tablets with leisure and health functions have come into being. At present, the market is mostly based on milk tablets and compound fruit and vegetable chewable tablets, which are leisure or health foods and are prepared with dietary fiber as raw materials. The production process of chewable tablets is simple. In modern processes, the production of chewable tablets using mixing tanks, tablet presses and other machines can meet the requirements of industrialization. At the same time, chewable tablets are easy to carry, easy to eat, and have a good taste, which are popular among the public. The development of compound functional chewable tablets will have broad market prospects. Summary of the invention

[0006] The purpose of the present invention is to provide a compound dietary fiber chewable tablet and a preparation method and application thereof. The compound dietary fiber chewable tablet has good shape, sweet and sour taste, is easy to carry, convenient to eat, can well supplement vitamin B6, selenium and dietary fiber; can reshape intestinal flora, enhance intestinal flora lactic acid and butyrate metabolism, regulate the body's immune state, prevent and alleviate symptoms of autoimmune diseases such as type 1 diabetes and rheumatoid arthritis; and has the function of lowering blood sugar and blood lipids, and is a pure natural, safe, sugar-free functional chewable tablet.

[0007] In order to achieve the above purpose, this application adopts the following technical solutions:

[0008] In a first aspect, the present invention provides a compound dietary fiber chewable tablet, which comprises the following raw materials in parts by weight: 900 parts of dietary fiber, 1-3 parts of vitamin B6, 0.01-0.03 parts of organic selenium, 70-80 parts of adhesive, 5-10 parts of citric acid, 3-5 parts of xylitol, and 5-15 parts of magnesium stearate; the dietary fiber is a mixture of konjac dietary fiber, Jerusalem artichoke dietary fiber, bamboo shoot dietary fiber and wheat bran dietary fiber.

[0009] In the above technical solution, the mass proportion of the konjac dietary fiber is 400-600 parts, the mass proportion of the Jerusalem artichoke dietary fiber is 100-400 parts, the mass proportion of the bamboo shoot dietary fiber is 80-120 parts, and the mass proportion of the wheat bran dietary fiber is 100-150 parts.

[0010] In the above technical solution, the adhesive is one of carrageenan, xanthan gum, mannitol, sodium alginate and methyl cellulose.

[0011] In the above technical solution, the organic selenium is Se-(methyl)selenocysteine ​​hydrochloride.

[0012] In a second aspect, the present invention provides a method for preparing a compound dietary fiber chewable tablet, comprising the following steps:

[0013] S1: Dietary fiber was prepared using konjac, Jerusalem artichoke, bamboo shoots and wheat bran as raw materials;

[0014] S2: Vitamin B6, organic selenium, citric acid, and xylitol were crushed and passed through a 100-mesh sieve;

[0015] S3: Prepare the components in the proportions of 900 parts of dietary fiber, 1-3 parts of vitamin B6, 0.01-0.03 parts of organic selenium, 70-80 parts of binder, 5-10 parts of citric acid, 3-5 parts of xylitol, and 5-15 parts of magnesium stearate, in parts by weight;

[0016] S4: taking the dietary fiber, vitamin B6, organic selenium, citric acid and xylitol prepared in S3, mixing them evenly, adding a binder, mixing evenly, and adding a wetting agent to make a soft material; drying at 40-50° C., granulating, and passing through a 20-mesh sieve; finally, adding magnesium stearate, and then wet-mixing and tableting to obtain the compound dietary fiber chewable tablet.

[0017] In the above technical scheme, in S1, konjac, Jerusalem artichoke, bamboo shoots and wheat bran are used as raw materials, and the Monascus fermentation method is used to extract dietary fiber, and the specific steps are as follows:

[0018] S11: The grinder grinds konjac, Jerusalem artichoke, bamboo shoots and wheat bran respectively until all of them pass through a 40-mesh sieve, and the four grinded samples are placed in an oven at 80°C overnight until constant weight is reached;

[0019] S12: preparing fermentation medium of four kinds of crushed samples: taking the crushed sample, glucose, (NH4)2SO4 and distilled water in S11, sterilizing them at high temperature, and preparing fermentation medium of the crushed sample; wherein the addition ratio is: crushed sample 5g: glucose 1g: (NH4)2SO4 0.4g: distilled water 100mL;

[0020] S13: inoculating 10% of Monascus seed liquid into the fermentation medium, and culturing in a shaker at 28° C. and 160 r / min for 7 days to obtain Monascus fermentation liquid;

[0021] S14: After 7 days, the fermentation liquid was filtered, 4 times the volume of ethanol was added to the filtrate, and the mixture was allowed to stand overnight. The precipitate was collected and freeze-dried to obtain konjac dietary fiber, Jerusalem artichoke dietary fiber, bamboo shoot dietary fiber and wheat bran dietary fiber respectively;

[0022] S15: The four dietary fibers obtained in S14 are mixed according to the weight proportions of 400-600 parts of konjac dietary fiber, 100-400 parts of Jerusalem artichoke dietary fiber, 80-120 parts of bamboo shoot dietary fiber, and 100-150 parts of wheat bran dietary fiber to obtain the dietary fiber.

[0023] In the above technical solution, in S4, the wetting agent is a 70% ethanol aqueous solution.

[0024] In a third aspect, the present invention provides the above-mentioned compound dietary fiber chewable tablets and the use of the above-mentioned compound dietary fiber chewable tablets prepared by the above-mentioned preparation method in reshaping intestinal flora and enhancing the lactic acid and butyrate metabolism levels of intestinal flora.

[0025] In a fourth aspect, the present invention provides the above-mentioned compound dietary fiber chewable tablets and the use of the above-mentioned compound dietary fiber chewable tablets prepared by the above-mentioned preparation method in the preparation of drugs for preventing and treating type 1 diabetes and rheumatoid arthritis.

[0026] In a fifth aspect, the present invention provides the above-mentioned compound dietary fiber chewable tablets and the use of the above-mentioned compound dietary fiber chewable tablets prepared by the above-mentioned preparation method in the preparation of drugs for preventing and treating hyperglycemia and hyperlipidemia.

[0027] The compound dietary fiber chewable tablets provided by the present invention are made of konjac, Jerusalem artichoke, bamboo shoots, wheat bran, vitamin B6, and organic selenium. The raw materials are natural, the product is sweet and sour, smooth, and easy to eat. It can well supplement vitamins, selenium, and dietary fiber. The product not only retains the various nutrients of the raw materials, but also has synergistic synergy between the ingredients, can reshape the intestinal flora, significantly improve the abundance of Lactobacillaceae and Akkermansiaceae, enhance the lactic acid and butyrate metabolism of the intestinal flora, regulate the immune state of the body, and can prevent and alleviate autoimmune diseases such as type 1 diabetes and rheumatoid arthritis; and has the function of lowering blood sugar and blood lipids. Animal experiments have shown that the compound dietary fiber chewable tablets provided by the present invention can reshape the intestinal flora, regulate the activation level of the body's immune cells, effectively reduce the random blood sugar value of type 1 diabetic mice and the incidence of type 1 diabetes, and can be used to prevent and treat autoimmune diseases such as type 1 diabetes and rheumatoid arthritis; and can reduce the random blood sugar and blood lipids of mice on a high-fat diet, and enhance insulin sensitivity.

[0028] Specifically, the present invention has the following outstanding advantages over the prior art:

[0029] 1. The raw materials are natural and the proportions are reasonable. The chewable tablets are made of konjac, Jerusalem artichoke, bamboo shoots, wheat bran, vitamin B6, and organic selenium. Among them, konjac and Jerusalem artichoke are rich in soluble dietary fiber, which are hydrophilic, absorb water, and hold water. They have strong water absorption and can dissolve in water and swell by absorbing water, which can make people feel full, prolong the time that food stays in the stomach, reduce the amount of food eaten, and can wrap and discharge oil and sugar substances from the body to achieve the purpose of helping to lose weight. At the same time, it slows down the speed of sugar absorption so that blood sugar will not rise sharply after a meal, which is helpful for stabilizing the condition of diabetic patients, and can be fermented by microorganisms in the large intestine and converted into bacterial energy, which is conducive to the reproduction of normal intestinal flora; bamboo shoots and wheat bran are rich in insoluble dietary fiber, which is not easily fermented by bacteria, can promote gastrointestinal motility, speed up the time for food to pass through the gastrointestinal tract, and accelerate defecation to reduce the time that harmful substances in feces come into contact with the intestine. In addition, insoluble fiber absorbs water in the large intestine to soften the stool, increase the volume of the stool, and can prevent constipation.

[0030] 2. Protective effect on cardiovascular and immune systems. Vitamin B6 and Se-methylselenocysteine ​​work synergistically to protect cardiovascular system and regulate the body's immune system, which is of great significance for the prevention and treatment of patients with autoimmune diseases such as rheumatoid arthritis, celiac disease, Crohn's disease, and ulcerative colitis.

[0031] 3. Animal experiments have shown that the compound dietary fiber chewable tablets provided by the present invention can improve the structure of intestinal flora, enhance the metabolism of lactic acid and butyrate of intestinal flora, and reduce the activation level of the immune system; effectively reduce the random blood glucose value and the incidence of type 1 diabetes in type 1 diabetic mice, and can be used to prevent and treat autoimmune diseases such as type 1 diabetes and rheumatoid arthritis.

[0032] 4. The chewable tablets are sweet and sour, smooth in taste, convenient to eat and easy to swallow. They have a large surface area and can promote the dissolution and absorption of vitamin B6, selenium and dietary fiber in the body. They have good effects and are a daily health food with good market prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] Figure 1 The effect of the chewable tablet of the present invention on the intestinal motility function of mice;

[0034] Figure 2 The effect of the chewable tablet of the present invention on the intestinal tissue morphology and intestinal mucosal barrier;

[0035] Figure 3 is the effect of the chewable tablet of the present invention on the intestinal flora;

[0036] Figure 4 It is the regulation of intestinal metabolites by the chewable tablet of the present invention;

[0037] Figure 5 The chewable tablet of the present invention regulates the immune system and delays the progression of type 1 diabetes in NOD mice.

[0038] Figure 6 The effect of the chewable tablet of the present invention on the body weight and blood sugar of mice;

[0039] Figure 7 The effect of the chewable tablet of the present invention on the insulin level of mice;

[0040] Figure 8 The present invention is the effect of the chewable tablet on serum triglyceride (TG) and total cholesterol (TC) in mice. DETAILED DESCRIPTION

[0041] In order to better illustrate the purpose, technical solutions and advantages of the present invention, the present invention will be further described below in conjunction with specific embodiments. The present invention can be implemented in many different forms and should not be construed as being limited to the embodiments set forth herein. On the contrary, these embodiments are provided so that this disclosure will be thorough and complete, and the concept of the present invention will be fully conveyed to those skilled in the art, and the present invention will only be limited by the claims.

[0042] Unless otherwise specified, various raw materials, reagents, instruments and equipment used in the present invention can be purchased from the market or prepared by existing methods.

[0043] 1. Raw materials introduction

[0044] 1. Dietary fiber

[0045] The Chinese Nutrition Society defines dietary fiber as follows: Dietary fiber generally refers to polysaccharide food components that are not easily digested by digestive enzymes, mainly from plant cell walls, including cellulose, hemicellulose, resin, pectin and lignin. Dietary fiber is divided into two basic types according to its water solubility, namely: soluble dietary fiber (SDF) and insoluble dietary fiber (IDF). Soluble fiber is divided into pectin, β-glucan, galactomannan gum, inulin and a large number of indigestible oligosaccharides, mainly from pectin, seaweed, konjac, etc.; insoluble fiber is divided into three categories: lignin, cellulose and hemicellulose, mainly from whole grains, including grains such as wheat, rice and beans, as well as vegetables and fruits.

[0046] In the composite dietary fiber chewable tablet provided by the present invention, dietary fiber is extracted from konjac, Jerusalem artichoke, bamboo shoots, and wheat bran as raw materials, and soluble dietary fiber and insoluble dietary fiber synergize to achieve the purpose of lowering blood sugar, lowering blood lipids, and regulating immunity. The main reason is that each component has the following effects:

[0047] Konjac (scientific name: Amorphophallus) is a general term for perennial herbaceous plants of the genus Amorphophallus in the family Araceae. Konjac mainly contains polysaccharides, such as glucomannan, mannan, etc.; organic acids, such as citric acid, cinnamic acid, heneicosene, etc.; glycosides, such as 3,4-dihydroxybenzaldehyde glucoside, etc. In addition, it also contains a variety of amino acids, crude protein and other ingredients. The content of glucomannan in white konjac is relatively high, and the content of glucomannan in dry matter can reach more than 60%, while the starch content is relatively low. Konjac has long been widely known as a food, and there are hundreds of varieties of it; Konjac can also be used as an excipient, thickener, emulsifier and filler. In addition, konjac glucomannan also has a health-care effect, which is to adjust the balance of nutrients in the body and reduce and avoid a series of cardiovascular and digestive diseases caused by high nutrient intake.

[0048] Jerusalem artichoke (Helianthus tuberosus L.): A perennial herbaceous plant of the Asteraceae family and the genus Helianthus. The main components of Jerusalem artichoke powder are inulin, crude fiber and rich minerals. Fresh Jerusalem artichoke tubers contain about 15%-20% inulin, accounting for about 70% of the dry weight of Jerusalem artichoke, and 70%-80% of which are oligofructose, 79.8% water, 1.0% protein, 2.8% ash, 16.6% crude fiber and certain vitamins. Inulin, as a natural functional edible polysaccharide, has the physiological functions of water-soluble dietary fiber and biologically active precursors, and has therefore been widely used in low-calorie, low-sugar, and low-fat foods. In addition, inulin is prepared from the tubers of plants such as Jerusalem artichoke, and then directly produced by enzymatic hydrolysis to produce high-purity fructose, which has the advantages of simple process, high conversion rate, and pure product.

[0049] Bamboo is a perennial herbaceous plant of the Gramineae family and the genus Bambusa. Its stems are mostly woody, but also herbaceous, slightly hollow in the middle, with many and dense nodes. Bamboo shoots are its young shoots, which are a renewable and nutritious food. Dietary fiber is rich in bamboo shoots, with the content of crude fiber reaching 58g in every 100g of bamboo shoots. It is one of the important nutrients in bamboo shoots. Bamboo shoot dietary fiber is mainly composed of cellulose, hemicellulose, lignin and polysaccharides. It has better water and oil retention capacity than other dietary fibers. The development and utilization of bamboo shoot dietary fiber has broad prospects.

[0050] Wheat (scientific name: Triticum aestivum L.) is an annual or biennial herbaceous plant of the Poaceae family and the genus Triticeae. Wheat bran is a by-product of flour processing, which refers to the outer epidermis (surface layer) collected during the process of peeling wheat grains. Wheat bran contains a variety of active substances, among which the main functional component is dietary fiber, which has a high water holding capacity, which is roughly 1.5-25 times its own mass and accounts for about 40% of the crude fiber mass. The main components of wheat bran are cellulose and hemicellulose, which account for 88% of the total cellulose content in wheat grains, and are representative insoluble dietary fibers.

[0051] The present invention adopts Monascus fermentation method, and uses konjac, Jerusalem artichoke, bamboo shoots and wheat bran as raw materials to extract dietary fiber. The specific preparation method of dietary fiber is as follows:

[0052] (1) Fresh konjac, Jerusalem artichoke, and wheat bran were washed, dried, and ground, and then passed through a 40-mesh sieve. The ground samples were placed in an oven at 80°C overnight until constant weight was achieved.

[0053] (2) Select fresh bamboo shoots without mechanical damage, decay or insect infestation, peel the shells, clean them, cut them into even-sized pieces (5-10 cm), squeeze them with a press to separate the bamboo shoot juice and bamboo shoot residue, squeeze the bamboo shoot residue for the second time, and dry the bamboo shoot residue; after drying, use a grinder to grind the bamboo shoot residue until it passes through a 40-mesh sieve, and place the crushed sample in an oven at 80°C overnight to a constant weight.

[0054] (3) Activation of Monascus: The frozen Monascus strains were streaked onto a sterilized slant potato glucose medium (20 g potato, 2 g glucose, 1.5-2 g agar, 100 ml water, heated and boiled to melt, then packaged and sterilized), cultured at 28°C for 7 days, and then expanded: a Monascus spore suspension was prepared with sterile saline and diluted to a concentration of 1 × 10 7 spores / mL.

[0055] (4) Preparation of Monascus seed liquid: Inoculate 10% of Monascus spore suspension into seed culture medium (3% glucose, 1.5% peptone, 0.1% MgSO4·H2O, 0.3% K2HPO4, 100 mL of distilled water, neutral pH, sterilized at 121°C for 20 min), and culture on a shaker at 28°C and 160 r / min for 3 days to obtain Monascus seed liquid.

[0056] (5) Preparation of fermentation medium: 5 g of the crushed sample in step 1, 1 g of glucose, 0.4 g of (NH4)2SO4, and 100 mL of distilled water, sterilize at 115°C for 20 min (scale up in equal proportions for mass production).

[0057] (6) inoculating 10% of Monascus seed liquid into the fermentation medium, and culturing in a shaker at 28° C. and 160 rpm for 7 days to obtain Monascus fermentation liquid;

[0058] (7) After 7 days, the fermentation liquid was filtered, and 4 times the volume of ethanol was added to the filtrate. The filtrate was allowed to stand overnight, and the precipitate was collected and freeze-dried to obtain konjac, Jerusalem artichoke, bamboo shoot, and wheat bran dietary fibers, respectively. Among them, the main products of konjac and Jerusalem artichoke were soluble dietary fiber, while the main products of bamboo shoot and wheat bran were insoluble dietary fiber.

[0059] 2. Vitamin B6

[0060] Vitamin B6, also known as pyridoxine, includes pyridoxine, pyridoxal and pyridoxamine. It exists in the body in the form of phosphate and is a type of B vitamin. Vitamin B6 is a water-soluble vitamin and an important component of coenzymes. It participates in the normal metabolism of sugars, proteins and fats, and has a certain correlation with the production of white blood cells and hemoglobin. Clinical studies have shown that patients with rheumatoid arthritis, celiac disease, Crohn's disease, ulcerative colitis, etc. have lower levels of vitamin B6 in their bodies than normal people, indicating that supplementing vitamin B6 is of great significance for the prevention and treatment of autoimmune diseases. In addition, vitamin B6 can inhibit the formation of homocysteine ​​(a toxin known to affect the myocardium and the accumulation of cholesterol in the myocardium) and prevent arteriosclerosis.

[0061] 3. Organic selenium

[0062] Selenium (Se) is an essential trace element for the human body. It has the functions of promoting body development, anti-oxidation, protecting cardiovascular system, detoxification, etc. It is one of the indispensable trace elements in the life process of humans and animals. Selenium cannot be synthesized by the body itself, and its biological half-life is about 11 days. Therefore, selenium supplemented with food or supplements is metabolized quickly in the body. The soil in most parts of China is lacking in selenium, resulting in low selenium content in cultivated agricultural products, which ultimately leads to insufficient selenium in our food. The National Food and Nutrition Advisory Committee recommends that adults consume 50-200mcg of selenium per day, and the World Health Organization recommends that adults supplement 50-250mcg of selenium per day. Organic selenium is formed by biotransformation and amino acids, generally in the form of selenomethionine. It has the characteristics of low toxicity and high bioavailability, and is the best selenium source for human use. Se-methylselenocysteine ​​is a natural selenium-containing amino acid. It is also the third-generation nutritional enhancer approved by China CFDA and the US FDA. It is currently the safest and most easily absorbed form of organic selenium.

[0063] 2. Embodiment

[0064] Example 1-5 Preparation of compound dietary fiber chewable tablets, the prepared konjac, Jerusalem artichoke, bamboo shoots, wheat bran dietary fiber and vitamin B6, organic selenium, citric acid, xylitol powder, according to the formula amount, mixed, added with a binder, mixed, used 70% ethanol aqueous solution as a wetting agent to make a soft material, dried, granulated, passed through a 20-mesh sieve, added magnesium stearate as a lubricant, wet mixed tableting, to obtain a compound dietary fiber chewable tablet.

[0065] The formulations of the components of Examples 1-5 and the process parameters for their preparation are shown in Table 1 below.

[0066] Table 1: Formula and preparation process of each example

[0067]

[0068] Table 1 only lists some specific embodiments. In the above embodiments, the dietary fiber ratios of konjac, Jerusalem artichoke, bamboo shoots and wheat bran can also be selected in other combinations, and the total amount can be maintained at 900 parts; wherein, the mass portion of konjac is 400-600 parts, the mass portion of Jerusalem artichoke is 100-400 parts, the mass portion of bamboo shoots is 80-120 parts, and the mass portion of wheat bran is any value in 100-150 parts; vitamin B6 can be selected from 1-3 parts, and organic selenium can be selected from 0.01-0.03 parts.

[0069] In the above embodiment, the binder can also be selected from other values ​​between 70 and 80 parts; the binder can be selected from carrageenan, xanthan gum, mannitol, sodium alginate, or methylcellulose.

[0070] In the above embodiment, citric acid can be selected from other values ​​in the range of 5-10 parts; xylitol can be selected from other values ​​in the range of 3-5 parts; and magnesium stearate can be selected from other values ​​in the range of 5-15 parts.

[0071] 3. Chewable tablet hardness and friability test

[0072] The hardness of a tablet generally refers to its compressive strength, that is, the radial crushing force of the tablet. Hardness is not a simple physical concept, but a comprehensive indicator of mechanical properties such as material elasticity, plasticity, strength and toughness. An ideal chewable tablet should have both an appropriate lower and upper hardness limit. The lower hardness limit is required to provide the tablet with a certain compressive resistance to facilitate production, packaging and transportation. It can usually refer to the hardness requirements of ordinary tablets, that is, the hardness is above 50N and the tensile strength is preferably 1.5-3MPa. The upper hardness limit of chewable tablets should ensure that the tablets have suitable chewability to avoid damage to the teeth and mandible during chewing. The FDA recommends that chewable tablets should have a lower hardness value (such as <118N).

[0073] At the same time, tablets are inevitably subjected to vibration or friction during production and transportation, which may cause tablet breakage, capping, and cracking, affecting the overall appearance and use of the tablets. Therefore, tablet friability is an indicator that reflects the tablet's ability to resist shock and wear, and is also an important item in tablet quality standard inspection. It is generally measured using a tablet friability tester.

[0074] The chewable tablets prepared in Examples 1-5 were tested for hardness and friability. The specific testing methods are as follows:

[0075] Hardness: Use Vickers hardness tester to test hardness;

[0076] Friability: For tablets weighing 0.65g or less, take a number of tablets to make the total weight about 6.5g; for tablets weighing more than 0.65g, take 10 tablets; use a hair dryer to blow away the powder that falls off the tablets, weigh accurately, place in a cylinder, and rotate 100 times. Take out, remove the powder in the same way, weigh accurately, friability = weight loss / total weight; the weight loss shall not exceed 1%, and broken, cracked and crushed tablets shall not be detected. This test is generally performed only once. If the weight loss exceeds 1%, it should be repeated twice, and the average weight loss of 3 times shall not exceed 1%, and broken, cracked and crushed tablets shall not be detected. The specific test results are shown in Table 2.

[0077] Table 2: Hardness and brittleness test of each example

[0078] project Hardness(N) friability Example 1 67.3 0.091 Example 2 75.6 0.075 Example 3 80.1 0.073 Example 4 85.2 0.064 Example 5 89.0 0.059

[0079] 4. Verification of the functional effects of chewable tablets

[0080] Furthermore, in order to verify the protective effect of the compound dietary fiber chewable tablet of the present invention on the cardiovascular and immune systems, the inventors conducted a large number of experiments for verification, which are now described by taking the following experiments as an example.

[0081] Mice were handled according to the Implementation Rules for the Management of Medical Laboratory Animals. NOD mice and C57BL / 6 mice were maintained in an SPF-grade animal facility.

[0082] 1. Compound dietary fiber chewable tablets promote intestinal peristalsis and protect the intestinal mucosal barrier

[0083] The above two groups of C57BL / 6 mice: control group (HFD) and chewable tablet group (HFD+chewable tablet) were continuously fed for 8 weeks. The mice were fasted for more than 6 hours and given 10ul / g body weight of semi-solid activated carbon powder (carbon powder 1g / ml, 0.5% cmc-na dissolved; cmc-na swelled, soaked overnight and then dissolved carbon powder, 0.5% cmc-na can be left, carbon powder is prepared and used first, stirred for 1 hour). Pay attention to the uniformity of the gavage action and perform it after being proficient in the operation. After 20 minutes, the mice were anesthetized and killed with 10% chloral hydrate (10.0mL / kg), and the propulsion rate of semi-solid activated carbon powder in the small intestine was measured (intestinal propulsion rate (%) = black semi-solid paste propulsion length / total length of small intestine × 100%).

[0084] The results are as follows Figure 1 As shown in the results, the intestinal propulsion rate of the compound dietary fiber chewable tablets intervention group was significantly faster than that of the control group, indicating that the compound dietary fiber chewable tablets can promote intestinal peristalsis.

[0085] In addition, 0.5 cm in length of the same part of the mouse colon was taken, cleaned in physiological saline, clearly marked, and fixed with 10% neutral formaldehyde, generally not more than 48 hours, and then stored in 75% ethanol after 48 hours; dehydrated, paraffin embedded, sectioned, and then HE staining and Alcian blue staining: Alcian blue staining dyes the nuclei of colon epithelial absorptive cells red, and the mucus in goblet cells blue-purple. Combined with HE staining, the intestinal tissue morphology and intestinal mucosal barrier of the two groups of mice were observed.

[0086] The results are as follows Figure 2 As shown, there was no significant difference in the intestinal tissue morphology between the two groups of mice; the compound dietary fiber chewable tablets can significantly increase the thickness of the colon epithelial mucosa and have a certain protective effect on the intestinal mucosal barrier.

[0087] 2. Compound dietary fiber chewable tablets reshape intestinal flora and promote the synthesis of lactic acid and butyric acid

[0088] There are a large number of microorganisms living in the human body, especially intestinal microorganisms, which are the most important "endogenous environmental factors" of the human body. There are more than 100 bacterial genera and more than 400 bacterial species, which is about 10 times the number of human cells. Modern research shows that human health is closely related to intestinal microorganisms. Intestinal flora imbalance caused by various reasons will affect human health and lead to various diseases.

[0089] In recent years, intestinal flora has been considered as a possible pathogenic factor and therapeutic target for many diseases. They affect the body's metabolism and immune regulation. At the same time, the enzymes contained in the intestinal flora can degrade polysaccharides that are difficult to be directly digested and absorbed by the human body, and participate in the metabolism of substances such as proteins and amino acids. Its metabolites can play a role in physiological and pathological processes. Dietary fiber can promote the growth of beneficial bacteria in the intestines, improve the structure of the flora, and play a positive role in the prevention and treatment of diseases.

[0090] In order to explore the regulatory effect of compound dietary fiber chewable tablets on intestinal flora, the inventors purchased 30 healthy 6-week-old female NOD mice from Jiangsu Jicui, randomly divided into 2 groups, 15 mice in each group, and raised normally in an SPF environment animal room. The control group was fed with mouse maintenance feed; the chewable tablet group was fed with a customized feed containing 10% compound dietary fiber chewable tablets, and other conditions remained the same. After 4 weeks of continuous feeding, mouse fecal samples (at least 2 fresh feces per mouse) were taken, quickly frozen in liquid nitrogen and stored at -80°C, and intestinal flora metagenomic sequencing analysis was performed within one week.

[0091] like Figure 3 The workflow shown in A was to perform metagenomic sequencing on two groups of mice to explore the changes in their intestinal flora. Figure 3 As shown in B and 3C, after 4 weeks of feeding with chewable tablets, the intestinal flora of mice changed significantly; LEfSe (LDA Effect Size) analysis was used to evaluate the difference in relative abundance of species between the two groups. Figure 3 D is the evolutionary branch diagram, Figure 3 E is the LDA value distribution bar graph, and the results show that there are significant differences in the species abundance and structural composition of the intestinal flora between the two groups; specifically, Figure 3As shown in Figure F, after continuous feeding of the compound dietary fiber chewable tablets for 4 weeks, the abundance of Lactobacillaceae and Akkermansiaceae in the intestines of mice increased significantly. Lactobacillaceae is a lactic acid bacillus, whose metabolite lactic acid can maintain the body's immune homeostasis and has a preventive and therapeutic effect on autoimmune diseases such as type 1 diabetes; Akkermansiaceae is Akkermansia muciniphila, which was successfully isolated and identified in 2004 and is the first species of Verrucomicrobia. Due to its unique efficacy in metabolic diseases, cancer and immunotherapy, it has attracted a lot of attention and research, becoming a rising star in the next generation of probiotics (NPGs). Many studies have shown that compared with healthy mice, the abundance of Akk in the intestinal flora of metabolic disease model mice is reduced, and the corresponding symptoms of disease mice can be effectively improved after supplementing Akk; for example, oral administration of Akk can significantly improve the symptoms of intestinal mucosal barrier dysfunction and metabolic disorders in mice fed a high-fat diet; in type 2 diabetic mice, Akk is used in combination with metformin for treatment, and Akk can enhance the therapeutic effect of metformin, while also reducing the endotoxin content in the mouse blood and alleviating the symptoms of liver damage in mice; supplementing Akk with high-fat diet mice can prevent mouse atherosclerosis and reduce metabolic endotoxemia.

[0092] To verify the results of metagenomics, the inventors also conducted metabolomics testing, such as Figure 4 The workflow is shown in A. Metabolomics analysis was performed on the feces of two groups of mice. Figure 4 As shown in B and 4C, after 4 weeks of chewable tablet feeding, the composition of intestinal metabolites in mice changed significantly; Figure 4 D. The analysis results showed that the levels of lactic acid, butyric acid, and butyrate in the intestinal metabolites increased significantly after 4 weeks of chewable tablet feeding; Figure 4 The results of E signaling pathway enrichment analysis showed that tryptophan metabolic pathway, fatty acid synthesis pathway and VB6 metabolic pathway were significantly enriched.

[0093] The results showed that the compound dietary fiber chewable tablets can reshape the intestinal flora, significantly increase the abundance of Lactobacillaceae and Akkermansiaceae flora, protect the intestinal mucosal barrier, promote the biosynthesis of lactic acid, butyric acid, butyrate, etc.; and have a certain preventive and therapeutic effect on autoimmune diseases such as obesity, atherosclerosis and type 1 diabetes.

[0094] 3. Compound dietary fiber chewable tablets regulate the immune system and delay the progression of type 1 diabetes in NOD mice

[0095] exhibition

[0096] Type 1 diabetes (T1D), also known as insulin-dependent diabetes mellitus (IDDM) or juvenile diabetes, is an autoimmune disease that occurs mostly in children and adolescents, but can also occur at any age. Its fundamental mechanism is that the pancreatic β cells responsible for producing insulin are mistakenly destroyed by the autoimmune system, resulting in endogenous insulin deficiency and causing hyperglycemia.

[0097] In order to explore the effect of compound dietary fiber chewable tablets on autoimmune diseases such as T1D and possible functional mechanisms, the above-mentioned NOD mice were continued to be raised in the SPF environment animal room, and the conditions remained unchanged: the control group was fed with maintenance feed, and the chewable tablet group was fed with a customized feed containing 10% compound dietary fiber chewable tablets. Blood sugar was continuously monitored every week. Two consecutive random blood sugars greater than 13.8mmol / L were considered to have type 1 diabetes. The incidence of the two groups of mice was counted. When the incidence of T1D in any group of mice exceeded 80%, the experiment was terminated. At the same time, the pancreas of the two groups of mice was taken for HE staining and immunofluorescence staining to determine and compare the severity of insulitis, including the degree of destruction of pancreatic islets and islet cells, and the infiltration of inflammatory cells. The proportion and activation state of effector T cells (Th1, Th17) and Treg cells in the spleen, pancreatic draining lymph nodes (PLN) and intestinal lamina propria lymphocytes were analyzed and compared. The regulatory effect of the chewable tablets of the present invention on the immune system was explored.

[0098] Further, the intestinal lamina propria lymphocyte separation method is:

[0099] (1) Separate the colon, squeeze out the contents in the colon, wash the large intestine with pre-cooled CMF-A, then cut the intestine longitudinally, cut off the connective tissue on the mesentery, and rinse the inner wall of the large intestine several times with 4°C pre-cooled CMF-A; place the large intestine in a culture dish containing pre-cooled CFM-A, pick it up with forceps and shake it, and wash it three times in sequence.

[0100] (2) Cut the colon into small pieces of approximately 2 ml, transfer them into a centrifuge tube containing 10 ml of CMF-B, and shake at 100 rpm and 37°C for 10 min to remove IELs (intraepithelial lymphocytes).

[0101] (3) Remove the tissue filter after IEL and rinse the colon tissue three times with pre-cooled CFM-A; transfer the rinsed colon tissue to an EP tube containing 0.5 ml LPL digestion solution (preheated at 37°C), chop it again into a paste, and then transfer it to a centrifuge tube with 4.5 ml LPL digestion solution; shake at 37°C, 150 rpm for 20 min.

[0102] (4) Add 10 ml of stop solution to terminate the digestion reaction, gently grind the digested intestinal tissue, and filter the solution through a 70 μm filter into a new 50 ml centrifuge tube.

[0103] (5) Centrifuge at 500G for 5 min, carefully pour off the supernatant, and be careful not to discard the precipitate; wash once with 10ml of 1640 to remove the digestive enzymes, filter through a 40um filter again (do not grind), centrifuge at 500G / 5min, pour off the supernatant, and resuspend the cells in 4ml of 1640. This step produces intestinal lamina propria cells.

[0104] (6) Take a new 15 ml centrifuge tube, place 5 ml of mouse lymphocyte separation solution at the bottom, tilt the tube wall, and slowly and gently add the resuspended intestinal lamina propria cells mentioned above.

[0105] (7) 800G, up 3 times, down 1 times, after centrifugation for 20 minutes, the liquid can be seen to be divided into three layers. Pipette out impurities in the upper layer 1640 until it is about 1 cm away from the middle layer. Carefully pipette the cells in the middle layer into a new centrifuge tube, wash the cells with 1640 and centrifuge at 300G for 5 minutes. Repeat twice to obtain the intestinal lamina propria lymphocytes.

[0106] like Figure 5 As shown in A and 5B, the incidence of T1D in the chewable tablet group was significantly reduced, and the onset time was delayed; compared with the control group, the spleen and pancreatic drainage lymph nodes in the chewable tablet group showed milder inflammatory reactions and smaller volumes; Figure 5 C As shown in the results of pancreatic immunofluorescence staining, the infiltration of pancreatic inflammatory cells in the chewable tablet feeding group was lighter, the destruction of pancreatic islet cells was significantly weakened, and the overall T1D disease phenotype in the chewable tablet group showed a remission trend.

[0107] Flow cytometry was used to compare the ratio and activation status of effector T cells (Th1, Th17) and Treg cells in the spleen and pancreatic draining lymph nodes (PLN). Figure 5 As shown in 5D, 5E, 5F, 5G, 5H, 5I, 5J, and 5K, there was no significant change in the proportion of CD4+T cells in the chewable tablet feeding group, but its activation level was significantly reduced, as shown by a significant increase in the proportion of CD44-CD62L+ cell subsets; the proportion of Th1 cells in effector T cells showed a downward trend, and there was no significant change in Th2 and Th17 subsets; at the same time, the proportion of Treg cell subsets showed an increasing trend, and the overall activation level of the immune system decreased.

[0108] 4. Hypoglycemic effect of compound dietary fiber chewable tablets

[0109] Twenty healthy male 8-week-old C57BL / 6 mice were purchased from Jiangsu Jicui and randomly divided into two groups, 10 mice in each group, and high-fat feeding was carried out in an SPF animal room, a control group (HFD) and a chewable tablet group (HFD+chewable tablets), wherein: the control group (HFD) was fed a high-fat diet and gavaged with 0.5 ml of normal saline per time per day; the chewable tablet group (HFD+chewable tablets) was fed a high-fat diet and gavaged with 0.5 g of chewable tablets per time per day (the compound dietary fiber chewable tablets provided in Example 3).

[0110] Feeding continued for 4 weeks, and body weight changes and random blood sugar levels were monitored weekly. Figure 6 .Depend on Figure 6 A shows that the compound dietary fiber chewable tablets can significantly alleviate obesity induced by a high-fat diet (*P<0.05) and maintain the blood sugar level of mice at a relatively normal level. Figure 6 As shown in B, it shows that the compound dietary fiber chewable tablets have the effect of lowering blood sugar and also have a certain preventive effect on obesity.

[0111] 5. Regulatory effect of compound dietary fiber chewable tablets on insulin levels in mice

[0112] Twenty 8-week-old C57BL / 6 male mice were randomly divided into two groups, 10 in each group, and fed with high-fat diet in an SPF animal room, a control group (HFD) and a chewable tablet group (HFD+chewable tablets), wherein: the control group (HFD) was fed with a high-fat diet and gavaged with 0.5 ml of normal saline per day; the chewable tablet group (HFD+chewable tablets) was fed with a high-fat diet and gavaged with 0.5 g of chewable tablets per day (compound dietary fiber chewable tablets provided in Example 3). At 4 weeks, blood was collected from each group of mice through the orbital venous plexus, 3000 rpm / min, 20 minutes to separate serum, and stored at 4°C. The level of insulin (INS) in serum was determined by Elisa kit, and the results are as follows: Figure 7 As shown in A, the serum insulin level in the compound dietary fiber chewable tablets intervention group was higher.

[0113] After 4 weeks of feeding, the glucose tolerance test (IGTT) and insulin sensitivity test (ITT) were performed.

[0114] Glucose tolerance test (IGTT): The mice were fasted for 16 hours in advance. During the fasting period, the mice maintained normal drinking water. The animals were placed in the animal room at 8 am the next day to start the glucose tolerance test. The fasting basal blood sugar was measured and recorded as the blood sugar value at 0 min. The mice were weighed at the same time. The mice were injected with glucose solution using a 1 ml syringe according to the standard intraperitoneal injection operation. The injection volume was determined according to the weight of the mice, with 0.01 ml injected for every gram of body weight. The timing started from the moment the injection was completed. The blood sugar value of each mouse was measured at 15 min, 30 min, 60 min, 90 min, and 120 min. The results are as follows: Figure 7 As shown in B: After receiving high-concentration glucose stimulation, the blood sugar fluctuation range of the compound dietary fiber chewable tablets intervention group was significantly smoother than that of the control group, indicating that they had more insulin reserves.

[0115] Insulin sensitivity test (ITT): The mice were fasted for 16 hours in advance. During the fasting period, the mice maintained normal drinking water. The animals were placed in the animal room at 8 am the next day to start the insulin sensitivity test. The fasting basal blood sugar was measured and recorded as the blood sugar value at 0 min. The mice were weighed at the same time. The mice were gently picked up and injected with insulin solution using a 1 ml syringe according to the standard intraperitoneal injection operation. The injection volume was determined according to the weight of the mouse. 5ul was injected for every gram of body weight (calculated at 0.5U / kg injection volume, 5ul / g body weight injection). The timing started from the moment the injection was completed. The blood sugar value of each mouse at each time point was measured at 15min, 30min, 60min, 90min, and 120min. The results are as follows: Figure 7 As shown in C: After receiving high-concentration insulin stimulation, the blood sugar level of the compound dietary fiber chewable tablet intervention group dropped faster and deeper, indicating that their insulin sensitivity was significantly higher than that of the control group.

[0116] 6. The lipid-lowering effect of compound dietary fiber chewable tablets

[0117] Twenty healthy male 8-week-old C57BL / 6 mice were randomly divided into two groups, 10 mice in each group, and fed with high-fat diet in an SPF animal room, a control group (HFD) and a chewable tablet group (HFD+chewable tablets), wherein: the control group (HFD) was fed with a high-fat diet and gavaged with 0.5 ml of normal saline per day; the chewable tablet group (HFD+chewable tablets) was fed with a high-fat diet and gavaged with 0.5 g of chewable tablets per day (the compound dietary fiber chewable tablets provided in Example 3).

[0118] After 4 weeks of feeding, blood was collected from each group of mice through the orbital venous plexus, and serum was separated at 3000rpm / min for 20min and stored at 4°C. Serum triglyceride (TG) and total cholesterol (TC) levels were measured using Nanjing Jiancheng TG / TCH detection kit (A110-1-1 and A111-1-1). The results are shown in Figure 8 As shown in the data, the serum triglyceride (TG) and total cholesterol (TC) levels in the compound dietary fiber chewable tablets intervention group were lower than those in the control group, indicating that the compound dietary fiber chewable tablets have the effect of lowering blood lipids and can be used for the prevention and treatment of hyperlipidemia.

[0119] Combined with the above results, the overall analysis shows that the chewable compound dietary fiber tablets can reshape the intestinal flora, protect the intestinal mucosal barrier, and promote the biosynthesis of lactic acid, butyric acid, butyrate, etc.; metabolites such as lactic acid, butyric acid, butyrate, etc. can affect the metabolism and differentiation development of immune cells, ultimately manifesting as a decrease in the overall CD4+T cell activation level, inhibiting Th1 cell differentiation while promoting Treg cell subset differentiation, maintaining the stability of the body's immune system, and having a certain preventive and therapeutic effect on autoimmune diseases such as type 1 diabetes; at the same time, it can lower blood sugar and blood lipids, enhance insulin sensitivity, and has a certain protective effect on the body's metabolic disorders.

[0120] Obviously, the above embodiments are merely examples for the purpose of clear explanation, and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived therefrom are still within the scope of protection of the invention.

Claims

1. A compound dietary fiber chewable tablet, characterized in that: The compound dietary fiber chewable tablet comprises the following raw materials in parts by weight: 900 parts of dietary fiber, 1-3 parts of vitamin B6, 0.01-0.03 parts of organic selenium, 70-80 parts of adhesive, 5-10 parts of citric acid, 3-5 parts of xylitol, and 5-15 parts of magnesium stearate; the dietary fiber is a mixture of konjac dietary fiber, Jerusalem artichoke dietary fiber, bamboo shoot dietary fiber and wheat bran dietary fiber.

2. The compound dietary fiber chewable tablet according to claim 1, characterized in that: The mass proportion of the konjac dietary fiber is 400-600 parts, the mass proportion of the Jerusalem artichoke dietary fiber is 100-400 parts, the mass proportion of the bamboo shoot dietary fiber is 80-120 parts, and the mass proportion of the wheat bran dietary fiber is 100-150 parts.

3. The compound dietary fiber chewable tablet according to claim 1, characterized in that: The adhesive is one of carrageenan, xanthan gum, mannitol, sodium alginate and methyl cellulose.

4. The compound dietary fiber chewable tablet according to claim 1, characterized in that: The organic selenium is Se-(methyl)selenocysteine ​​hydrochloride.

5. A method for preparing a compound dietary fiber chewable tablet, characterized in that: The following steps are involved: S1: preparing dietary fiber using konjac, Jerusalem artichoke, bamboo shoots and wheat bran as raw materials; S2: Vitamin B6, organic selenium, citric acid, and xylitol were crushed and passed through a 100-mesh sieve; S3: Prepare the components in the proportions of 900 parts of dietary fiber, 1-3 parts of vitamin B6, 0.01-0.03 parts of organic selenium, 70-80 parts of binder, 5-10 parts of citric acid, 3-5 parts of xylitol, and 5-15 parts of magnesium stearate, in parts by weight; S4: Take the dietary fiber, vitamin B6, organic selenium, citric acid, and xylitol prepared in S3, mix them evenly, add a binder, mix evenly, and add a wetting agent to make a soft material; dry at 40-50°C, granulate, and pass through a 20-mesh sieve; Finally, magnesium stearate is added, and wet mixing and tableting are performed to obtain the compound dietary fiber chewable tablet.

6. The preparation method according to claim 5, characterized in that: In S1, konjac, Jerusalem artichoke, bamboo shoots and wheat bran are used as raw materials, and the Monascus fermentation method is used to extract dietary fiber. The specific steps are as follows: S11: The grinder grinds konjac, Jerusalem artichoke, bamboo shoots and wheat bran respectively until all of them pass through a 40-mesh sieve, and the four grinded samples are placed in an oven at 80°C overnight until constant weight is reached; S12: preparing fermentation medium of four kinds of crushed samples: taking the crushed sample, glucose, (NH4)2SO4 and distilled water in S11, sterilizing them at high temperature, and preparing fermentation medium of the crushed sample; wherein the addition ratio is: crushed sample 5g: glucose 1g: (NH4)2SO4 0.4g: distilled water 100mL; S13: inoculating 10% of Monascus seed liquid into the fermentation medium, and culturing in a shaker at 28° C. and 160 r / min for 7 days to obtain Monascus fermentation liquid; S14: After 7 days, the fermentation liquid was filtered, 4 times the volume of ethanol was added to the filtrate, and the mixture was allowed to stand overnight. The precipitate was collected and freeze-dried to obtain konjac dietary fiber, Jerusalem artichoke dietary fiber, bamboo shoot dietary fiber and wheat bran dietary fiber respectively; S15: The four dietary fibers obtained in S14 are mixed according to the weight proportions of 400-600 parts of konjac dietary fiber, 100-400 parts of Jerusalem artichoke dietary fiber, 80-120 parts of bamboo shoot dietary fiber, and 100-150 parts of wheat bran dietary fiber to obtain the dietary fiber.

7. The preparation method according to claim 5, characterized in that: In S4, the wetting agent is a 70% ethanol aqueous solution.

8. Use of the compound dietary fiber chewable tablet according to any one of claims 1 to 4 and the compound dietary fiber chewable tablet prepared by the preparation method according to any one of claims 5 to 7 in reshaping intestinal flora and enhancing the lactic acid and butyrate metabolism levels of intestinal flora.

9. Use of the compound dietary fiber chewable tablet according to any one of claims 1 to 4 and the compound dietary fiber chewable tablet prepared by the preparation method according to any one of claims 5 to 7 in the preparation of drugs for preventing and treating type 1 diabetes and rheumatoid arthritis.

10. Use of the compound dietary fiber chewable tablet according to any one of claims 1 to 4 and the compound dietary fiber chewable tablet prepared by the preparation method according to any one of claims 5 to 7 in the preparation of drugs for preventing and treating hyperglycemia and hyperlipidemia.